Table 2.
Multiple sclerosis descriptive variables.
| Variable | Mean (SD) or N (%) |
|---|---|
| Disease duration | 16.71 (11.22) |
| Disease course | |
| Relapsing remitting | 318 (64.8%) |
| Secondary progressive | 81 (16.5%) |
| Primary progressive | 50 (10.2%) |
| Unknown or no answer | 37 (7.5%) |
| Clinically isolated syndrome | 5 (1.0%) |
| Disease modifying therapy | |
| Increased risk | 194 (39.5%) |
| Ocrelizumab | 85 (17.3%) |
| Dimethyl fumarate | 45 (9.2%) |
| Fingolimod | 30 (6.1%) |
| Teriflunomide | 22 (4.5%) |
| Alemtuzumab | 9 (1.8%) |
| Siponimod | 1 (0.2%) |
| Cladribine | 1 (0.2%) |
| Diroximel fumarate | 1 (0.2%) |
| No additional risk | 129 (26.3%) |
| Glatiramer acetate | 64 (13.0%) |
| Interferons | 38 (7.7%) |
| Natalizumab | 27 (5.5%) |
| Other/off-label | 20 (4.1%) |
| No DMT | 148 (30.1%) |
| Disability (PDDS) | |
| 0 | 95 (19.3%) |
| 1 | 95 (19.3%) |
| 2 | 64 (13.0%) |
| 3 | 63 (12.8%) |
| 4 | 63 (12.8%) |
| 5 | 37 (7.5%) |
| 6 | 43 (8.8%) |
| 7 | 28 (5.7%) |
| 8 | 1 (0.2%) |
| No answer | 2 (0.4%) |